Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wir
DAK-Gesundheit awarded a contract of undisclosed value to Ipsen Pharma GmbH for Healthcare & Medical in May 2026 — one of 389 awards this buyer has made.
Buying agency
DAK-GesundheitWinning supplier
Ipsen Pharma GmbHContract description
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Lanreotid, ATC H01CB03 für die Zeit 01.07.2025 - 30.06.2026 (zzgl. Verlängerungsoption 1x 12 Monate)
Related awards · DAK-Gesundheit
389 awardsThe buyer's full award list ranked by value, with the winning supplier, date and sector on every row — plus CSV / API export.
- ocds-ted-210283-2024Aktivital GmbH€9.1M10 Apr 2024 Healthcare
- ocds-ted-211590-2024Kraaibeek GmbH€2.5M10 Apr 2024 Healthcare
- ocds-ted-828775-2025news aktuell GmbH€38.0K12 Dec 2025 IT
Other wins · Ipsen Pharma GmbH
13 winsThe supplier's complete win history across every buyer it sells to — not just the handful shown here.
- ocds-ted-205136-2025GWQ ServicePlus AG€131 Mar 2025 Healthcare
- ocds-ted-430178-2025DAK-Gesundheit€103 Jul 2025 Healthcare
- ocds-ted-319589-2026-2PBMG eGNot disclosed11 May 2026 Healthcare
Premium · full dataset
See the full award context.
Competing bids, award margins and every related contract for DAK-Gesundheit and Ipsen Pharma GmbH — one subscription unlocks everything.
Sign Up Free →Free account · cancel anytime · 14-day money-back